Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  4/25/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 4/25/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  4/25/2018
Tennessee Oncology / Sarah Cannon Research Institute
mi
from
Nashville, TN
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 4/25/2018
Tennessee Oncology / Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  4/25/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 4/25/2018
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated:  4/25/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of SC-007 in Subjects With Advanced Cancer
An Open Label Study of SC-007 in Subjects With Advanced Cancer
Status: Enrolling
Updated: 4/25/2018
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Jonsson Comprehensive Cancer Center at UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
VA Greater Los Angeles
mi
from
Los Angeles, CA
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
A Phase I Trial of CCL21 Gene Modified Dendritic Cells In Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
VA Greater Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways
Status: Enrolling
Updated:  4/26/2018
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
Phase II Study Evaluating Safety and Efficacy of Stereotactic Body Radiotherapy and Radiofrequency Ablation for Medically Inoperable and Recurrent Lung Tumors Near Central Airways
Status: Enrolling
Updated: 4/26/2018
UCLA Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated:  4/26/2018
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated: 4/26/2018
Veterans Administration Los Angeles Healthcare System
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated:  4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Undergoing Surgery
A Phase I Randomized, Double-Blind, Placebo-Controlled Two-Arm Study of Quercetin and Green Tea to Enhance the Bioavailability of Green Tea Polyphenols in Men Scheduled for Prostatectomy
Status: Enrolling
Updated: 4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Status: Enrolling
Updated:  4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus
Phase II Randomized Trial of Mugard Compared With Best Supportive Care for Prevention and Treatment of Stomatitis in Women With Hormone Receptor Positive Breast Cancer Initiating Treatment With Everolimus-based Endocrine Therapy.
Status: Enrolling
Updated: 4/26/2018
Jonsson Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Status: Enrolling
Updated:  4/26/2018
City of Hope Medical Center
mi
from
Duarte, CA
p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer
A Phase I Study of a p53MVA Vaccine in Combination With Gemcitabine in Ovarian Cancer
Status: Enrolling
Updated: 4/26/2018
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated:  4/26/2018
UCLA
mi
from
Los Angeles, CA
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated: 4/26/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated:  4/26/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Focal Laser Ablation of Prostate Tissue
Focal Laser Ablation of Prostate Tissue: A Pilot Feasibility Study Using MRI/US Image Fusion for Guidance
Status: Enrolling
Updated: 4/26/2018
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated:  4/26/2018
University of California at San Francisco
mi
from
San Francisco, CA
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer
Status: Enrolling
Updated: 4/26/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status: Enrolling
Updated:  4/26/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer
Status: Enrolling
Updated: 4/26/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Status: Enrolling
Updated:  4/26/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
A Randomized, Global, Open-label Study of Nivolumab in Combination With BMS-986205 vs Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck
Status: Enrolling
Updated: 4/26/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
San Diego, CA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
San Diego, CA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Jacksonville, FL
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Jacksonville, FL
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Decatur, GA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Decatur, GA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Marietta, GA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Marietta, GA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Wichita, KA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Wichita, KA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Boston, MA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Boston, MA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Bridgeton, MO
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Bridgeton, MO
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Lincoln, NE
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Lincoln, NE
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Cleveland, OH
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Cleveland, OH
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Gettysburg, PA
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Gettysburg, PA
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Greenville, SC
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Greenville, SC
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Fort Worth, TX
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Fort Worth, TX
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Lubbock, TX
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Lubbock, TX
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Fort Myers, FL
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Fort Myers, FL
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Saint Petersburg, FL
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Tallahassee, FL
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Tallahassee, FL
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
West Palm Beach, FL
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Louisville, KY
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Louisville, KY
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Lebanon, TN
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Lebanon, TN
Click here to add this to my saved trials
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  4/26/2018
Local Institution
mi
from
Darlinghurst,
An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
A Phase 3 Open Label, Randomized Study of BMS-986205 Combined With Nivolumab With or Without Chemotherapy Versus Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 4/26/2018
Local Institution
mi
from
Darlinghurst,
Click here to add this to my saved trials
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
Status: Enrolling
Updated:  4/27/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors
Status: Enrolling
Updated: 4/27/2018
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trimodality Management of T1b Esophageal Cancers
Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus
Status: Enrolling
Updated:  4/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Trimodality Management of T1b Esophageal Cancers
Phase IIB Study of Trimodality Management of Clinical T1bN0M0 Cancers of the Esophagus
Status: Enrolling
Updated: 4/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dasatinib and Crizotinib in Advanced Cancer
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies
Status: Enrolling
Updated:  4/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Dasatinib and Crizotinib in Advanced Cancer
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies
Status: Enrolling
Updated: 4/27/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study
Status: Enrolling
Updated:  4/27/2018
UCLA
mi
from
Los Angeles, CA
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer
Use of Laser Interstitial Thermal Therapy in the Focal Treatment of Localized Prostate Cancer: A Pilot Feasibility Study
Status: Enrolling
Updated: 4/27/2018
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer
A Phase II Study of Adjuvant Chemoradiation With Weekly Oxaliplatin in Patients With High Risk Resected Squamous Cell Carcinoma of the Head and Neck Region
Status: Enrolling
Updated:  4/27/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Adjuvant Chemoradiation With Weekly Oxaliplatin in Resected Head and Neck Cancer
A Phase II Study of Adjuvant Chemoradiation With Weekly Oxaliplatin in Patients With High Risk Resected Squamous Cell Carcinoma of the Head and Neck Region
Status: Enrolling
Updated: 4/27/2018
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated:  4/29/2018
Highland Hospital
mi
from
Rochester, NY
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated: 4/29/2018
Highland Hospital
mi
from
Rochester, NY
Click here to add this to my saved trials
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated:  4/29/2018
Pluta Cancer Center
mi
from
Rochester, NY
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated: 4/29/2018
Pluta Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated:  4/29/2018
University of Rochester Wilmot Cancer Center
mi
from
Rochester, NY
A Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
A Pilot Study of a Geriatric Assessment Intervention for Older Cancer Patients Receiving Chemotherapy
Status: Enrolling
Updated: 4/29/2018
University of Rochester Wilmot Cancer Center
mi
from
Rochester, NY
Click here to add this to my saved trials
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Status: Enrolling
Updated:  4/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer
A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer
Status: Enrolling
Updated: 4/30/2018
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
Status: Enrolling
Updated:  4/30/2018
University of Chicago
mi
from
Chicago, IL
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer
Status: Enrolling
Updated: 4/30/2018
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials